Drug intelligence / Profile preview

Rezole-ITR

Development stage: Unknown
Lead developer: Ritz Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Rezole-ITR** is a marketed oral fixed-dose capsule from Ritz Pharma containing **rabeprazole 20 mg** and **itopride hydrochloride 150 mg**. Rabeprazole is a proton-pump inhibitor that suppresses gastric acid secretion through inhibition of gastric hydrogen-potassium ATPase in parietal cells. Itopride is a gastroprokinetic agent that antagonizes dopamine D2 receptors and inhibits acetylcholinesterase, increasing gastrointestinal acetylcholine activity and promoting gastric motility and emptying. The combination is marketed for peptic ulcer, acid-related disorders, and gastroparesis.

Brand names: Rezole-ITR
Other names: Rabeprazole sodium + Itopride hydrochloride

Targets

DRD2 (Dopamine D2 Receptor)ButyrylcholinesteraseAcetylcholinesteraseATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Rezole-ITR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rezole-ITR.

Explore the full profile